Mild cognitive impairment (MCI) is an important prodromal stage of Alzheimer's disease (AD), affecting 69 million individuals worldwide. At present, there is a lack of a community-applicable tool for MCI screening. Exhaled breath volatile organic compounds (VOCs) have been used to distinguish MCI from cognitively normal (CN) individuals only in small sample size studies and the efficacy has not been compared with blood biomarkers.
Objective
This diagnostic study aimed to assess the feasibility of using exhaled breath VOCs detection by a portable micro-gas chromatography (μGC) device as a screening tool to discriminate MCI from CN individuals in a community population.
Methods
A detection model was developed and optimized from five distinct machine learning algorithms based on the differential VOCs between 240 MCI and 241 CN individuals. Among these 481 participants, five plasma biomarkers were measured in 397 individuals (166 MCI and 231 CN).
Results
The final model (481 individuals) incorporating eight differential VOCs showed good performance with an area under the receiver-operating characteristic curve (AUC) of 0.84 (95% confidence interval (95% CI): 0.83–0.85). The AUC of the VOC model (0.80, 95% CI: 0.69–0.90) was higher than that of the plasma model (0.77, 95% CI: 0.65–0.88) (397 individuals).
Conclusions
The detection of exhaled breath VOCs by a portable μGC device is feasible for MCI screening in community populations, potentially facilitating early detection and intervention strategies for individuals at high risk.
Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol2019; 18: 459–480.
3.
JiaLDuYChuL, et al.Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. Lancet Public Health2020; 5: e661–e671.
4.
GustavssonANortonNFastT, et al.Global estimates on the number of persons across the Alzheimer's disease continuum. Alzheimers Dement2023; 19: 658–670.
5.
The three stages of Alzheimer's disease. Lancet2011; 377: 1465.
6.
ScheltensPDe StrooperBKivipeltoM, et al.Alzheimer's disease. Lancet2021; 397: 1577–1590.
7.
VeroneseNSoysalPDemurtasJ, et al.Physical activity and exercise for the prevention and management of mild cognitive impairment and dementia: a collaborative international guideline. Eur Geriatr Med2023; 14: 925–952.
8.
LiWKimKRZhangD, et al.Cost-effectiveness of physical activity interventions for prevention and management of cognitive decline and dementia-a systematic review. Alzheimers Res Ther2023; 15: 159.
9.
PintoTCCMachadoLBulgacovTM, et al.Is the Montreal Cognitive Assessment (MoCA) screening superior to the Mini-Mental State Examination (MMSE) in the detection of mild cognitive impairment (MCI) and Alzheimer's disease (AD) in the elderly?Int Psychogeriatr2019; 31: 491–504.
TappenRMRosselliMEngstromG. Use of the MC-FAQ and MMSE-FAQ in cognitive screening of older African Americans, Hispanic Americans, and European Americans. Am J Geriatr Psychiatry2012; 20: 955–962.
12.
GuoYShenXNWangHF, et al.The dynamics of plasma biomarkers across the Alzheimer's continuum. Alzheimers Res Ther2023; 15: 31.
13.
SimrénJLeuzyAKarikariTK, et al.The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. Alzheimers Dement2021; 17: 1145–1156.
14.
SmolinskaAHauschildACFijtenRR, et al.Current breathomics–a review on data pre-processing techniques and machine learning in metabolomics breath analysis. J Breath Res2014; 8: 027105.
15.
FensNDoumaRASterkPJ, et al.Breathomics as a diagnostic tool for pulmonary embolism. J Thromb Haemost2010; 8: 2831–2833.
16.
KuoTCTanCEWangSY, et al.Human breathomics database. Database (Oxford)2020; 2020: baz139.
17.
GashimovaEMTemerdashevAZPorkhanovVA, et al.Volatile organic compounds in exhaled breath as biomarkers of lung cancer: advances and potential problems. J Anal Chem2022; 77: 785–810.
18.
LiuJChenHLiY, et al.A novel non-invasive exhaled breath biopsy for the diagnosis and screening of breast cancer. J Hematol Oncol2023; 16: 63.
19.
ChungJAkterSHanS, et al.Diagnosis by volatile organic compounds in exhaled breath from patients with gastric and colorectal cancers. Int J Mol Sci2023; 24: 129.
20.
PhillipsMCataneoRNCondosR, et al.Volatile biomarkers of pulmonary tuberculosis in the breath. Tuberculosis (Edinb)2007; 87: 44–52.
21.
ZhangPRenTChenH, et al.A feasibility study of COVID-19 detection using breath analysis by high-pressure photon ionization time-of-flight mass spectrometry. J Breath Res2022; 16: 046009.
22.
TrefzPObermeierJLehbrinkR, et al.Exhaled volatile substances in children suffering from type 1 diabetes mellitus: results from a cross-sectional study. Sci Rep2019; 9: 15707.
23.
HabibzadehAOstovanVRKeshavarzianO, et al.Volatile organic compounds analysis as promising biomarkers for Parkinson's disease diagnosis: a systematic review and meta-analysis. Clin Neurol Neurosurg2023; 235: 108022.
24.
JiaoBZhangSBeiY, et al.A detection model for cognitive dysfunction based on volatile organic compounds from a large Chinese community cohort. Alzheimers Dement2023; 19: 4852–4862.
25.
TieleAWicaksonoADaultonE, et al.Breath-based non-invasive diagnosis of Alzheimer's disease: a pilot study. J Breath Res2020; 14: 026003.
26.
LauHCYuJBLeeHW, et al.Investigation of exhaled breath samples from patients with Alzheimer's disease using gas chromatography-mass spectrometry and an exhaled breath sensor system. Sensors (Basel)2017; 17: 1783.
27.
BachJPGoldMMengelD, et al.Measuring compounds in exhaled air to detect Alzheimer's disease and Parkinson's disease. PLoS One2015; 10: e0132227.
28.
TischUSchlesingerIIonescuR, et al.Detection of Alzheimer's and Parkinson's disease from exhaled breath using nanomaterial-based sensors. Nanomedicine (Lond)2013; 8: 43–56.
29.
WangJNunoveroNNidetzR, et al.Belt-mounted micro-gas-chromatograph prototype for determining personal exposures to volatile-organic-compound mixture components. Anal Chem2019; 91: 4747–4754.
30.
ZangWLiuZKulkarniGS, et al.A microcolumn DC graphene sensor for rapid, sensitive, and universal chemical vapor detection. Nano Lett2021; 21: 10301–10308.
31.
HuangXSharmaRSivakumarAD, et al.Ultrathin silica integration for enhancing reliability of microfluidic photoionization detectors. Anal Chem2023; 95: 8496–8504.
32.
Wei-Hao LiMGhoshAVenkatasubramanianA, et al.High-sensitivity micro-gas chromatograph-photoionization detector for trace vapor detection. ACS Sens2021; 6: 2348–2355.
33.
SharmaRZangWZhouM, et al.Real time breath analysis using portable gas chromatography for adult asthma phenotypes. Metabolites2021; 11: 265.
34.
SharmaRZangWTabartehfarahaniA, et al.Portable breath-based volatile organic compound monitoring for the detection of COVID-19 during the circulation of the SARS-CoV-2 delta variant and the transition to the SARS-CoV-2 omicron variant. JAMA Netw Open2023; 6: e230982.
35.
ChatterjeePPedriniSDoeckeJD, et al.Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: a cross-sectional and longitudinal study in the AIBL cohort. Alzheimers Dement2023; 19: 1117–1134.
36.
JungYDamoiseauxJS. The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer's disease. Brain2024; 147: 12–25.
37.
ChatterjeePPedriniSAshtonNJ, et al.Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. Alzheimers Dement2022; 18: 1141–1154.
38.
BossuytPMReitsmaJBBrunsDE, et al.STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ2015; 351: h5527.
39.
WinbladBPalmerKKivipeltoM, et al.Mild cognitive impairment–beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med2004; 256: 240–246.
40.
Nardi-AgmonIAbud-HawaMLiranO, et al.Exhaled breath analysis for monitoring response to treatment in advanced lung cancer. J Thorac Oncol2016; 11: 827–837.
41.
BrickmanAMManlyJJHonigLS, et al.Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study. Alzheimers Dement2021; 17: 1353–1364.
42.
Stevenson-HoareJHeslegraveALeonenkoG, et al.Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease. Brain2023; 146: 690–699.
43.
WuXXiaoZYiJ, et al.Development of a plasma biomarker diagnostic model incorporating ultrasensitive digital immunoassay as a screening strategy for Alzheimer disease in a Chinese population. Clin Chem2021; 67: 1628–1639.
44.
GonzalesMMShortMISatizabalCL, et al.Blood biomarkers for dementia in Hispanic and non-Hispanic White adults. Alzheimers Dement (N Y)2021; 7: e12164.
45.
O'BryantSPetersenMHallJ, et al.Characterizing plasma NfL in a community-dwelling multi-ethnic cohort: results from the HABLE study. Alzheimers Dement2022; 18: 240–250.
46.
MazzatentaAPokorskiMSartucciF, et al.Volatile organic compounds (VOCs) fingerprint of Alzheimer's disease. Respir Physiol Neurobiol2015; 209: 81–84.
47.
Van GossumADecuyperJ. Breath alkanes as an index of lipid peroxidation. Eur Respir J1989; 2: 787–791.
48.
KneepkensCMLepageGRoyCC. The potential of the hydrocarbon breath test as a measure of lipid peroxidation. Free Radic Biol Med1994; 17: 127–160.
49.
JeejeebhoyKN. In vivo breath alkane as an index of lipid peroxidation. Free Radic Biol Med1991; 10: 191–193.
50.
DasuriKZhangLKellerJN. Oxidative stress, neurodegeneration, and the balance of protein degradation and protein synthesis. Free Radic Biol Med2013; 62: 170–185.
51.
Peña-BautistaCBaqueroMVentoM, et al.Free radicals in Alzheimer's disease: lipid peroxidation biomarkers. Clin Chim Acta2019; 491: 85–90.
52.
Benseny-CasesNKlementievaOCotteM, et al.Microspectroscopy (μFTIR) reveals co-localization of lipid oxidation and amyloid plaques in human Alzheimer disease brains. Anal Chem2014; 86: 12047–12054.
53.
ChalansonnetMCarabinNBoucardS, et al.Study of the potential oxidative stress induced by six solvents in the rat brain. Neurotoxicology2013; 35: 71–83.
54.
YuanLLiuJMaW, et al.Dietary pattern and antioxidants in plasma and erythrocyte in patients with mild cognitive impairment from China. Nutrition2016; 32: 193–198.
55.
WishartDSGuoAOlerE, et al.HMDB 5.0: the human metabolome database for 2022. Nucl Acids Res2022; 50: D622–d631.
56.
de Lacy CostelloBAmannAAl-KatebH, et al.A review of the volatiles from the healthy human body. J Breath Res2014; 8: 014001.
57.
GarnerCESmithSde Lacy CostelloB, et al.Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease. FASEB J2007; 21: 1675–1688.
58.
SalamiMTalebpourZAlizadehR. Fabrication of a new SPME fiber based on Polyacrylic acid/ MIL-88(Fe)-NH2 composite as a self-healing coating for the analysis of breast cancer biomarkers in the urine sample. J Pharm Biomed Anal2022; 219: 114902.
59.
WangYHanXLiJ, et al.Associations between the compositional patterns of blood volatile organic compounds and chronic respiratory diseases and ages at onset in NHANES 2003–2012. Chemosphere2023; 327: 138425.
60.
LiaoYLuoYDingN, et al.d-Glucuronolactone attenuates para-xylene-induced defects in neuronal development and plasticity in Xenopus tectum in vivo. Toxicology2020; 430: 152341.
61.
McKeeRHLammersJHMuijserH, et al.Neurobehavioral effects of acute exposure to aromatic hydrocarbons. Int J Toxicol2010; 29: 277–290.
62.
WangFLiCLiuW, et al.Potential mechanisms of neurobehavioral disturbances in mice caused by sub-chronic exposure to low-dose VOCs. Inhal Toxicol2014; 26: 250–258.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
